US 12,268,733 B2
Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
Anna Petryk, New Haven, CT (US)
Assigned to Alexion Pharmaceuticals, Inc., Boston, MA (US)
Appl. No. 17/265,894
Filed by Alexion Pharmaceuticals, Inc., Boston, MA (US)
PCT Filed Aug. 9, 2019, PCT No. PCT/US2019/045963
§ 371(c)(1), (2) Date Feb. 4, 2021,
PCT Pub. No. WO2020/033867, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/717,371, filed on Aug. 10, 2018.
Prior Publication US 2021/0162023 A1, Jun. 3, 2021
Int. Cl. A61P 35/00 (2006.01); A61B 6/03 (2006.01); A61K 38/18 (2006.01); A61K 38/46 (2006.01)
CPC A61K 38/465 (2013.01) [A61B 6/032 (2013.01); A61K 38/1875 (2013.01); A61P 35/00 (2018.01); C12Y 301/03001 (2013.01)] 19 Claims
 
1. A method of improving bone formation at a site of orthopedic hardware implantation in a subject with neurofibromatosis type 1 (NF1) or dystrophic scoliosis comprising:
administering a soluble alkaline phosphatase (sALP) to the subject before, during, and/or after at least one orthopedic surgery comprising implantation of the hardware, wherein the sALP is administered to the subject at a dosage providing from about 0.2 mg/kg/week to about 12 mg/kg/week, wherein administration of the sALP results in an increase in bone healing at the site of implantation of the hardware that results in new bone formation in the subject relative to an untreated subject.